Sensyne Health launches diabetes app in the UKUK digital health company Sensyne Health has launched a new smartphone app to help people across the diabetes Share XSensyne Health launches diabetes app in the UKhttps://pharmaphorum.com/news/sensyne-health-launches-diabetes-app-in-the-uk/
Novo Nordisk beats Q2 profit forecasts by cutting costsDenmark’s Novo Nordisk has beaten profit forecasts in the second quarter after overcoming tough conditions in the diabetes Share XNovo Nordisk beats Q2 profit forecasts by cutting costshttps://pharmaphorum.com/news/novo-nordisk-beats-q2-profit-forecasts-by-cutting-costs/
Indigo raises 38 million euros for ‘invisible’ diabetes glucose sensorMedical device company Indigo Diabetes has raised 38 million euros to develop an “invisible” sensor for people with Share XIndigo raises 38 million euros for ‘invisible’ diabetes glucose sensorhttps://pharmaphorum.com/news/indigo-raises-38-million-euros-for-invisible-diabetes-glucose-sensor/
Trial shows AZ’s Farxiga slows onset of chronic kidney disease and cuts mortalityAstraZeneca’s Farxiga could be on course for another use, after trial results showed it slowed the worsening of Share XTrial shows AZ’s Farxiga slows onset of chronic kidney disease and cuts mortalityhttps://pharmaphorum.com/news/azs-farxiga-slows-onset-of-chronic-kidney-and-cuts-mortality/
Biocon annouces digital diabetes tie-up with VoluntisBiocon has announced a deal with digital therapy specialist Voluntis, aiming to create personalised care for people with Share XBiocon annouces digital diabetes tie-up with Voluntishttps://pharmaphorum.com/news/biocon-annouces-digital-diabetes-tie-up-with-voluntis/
NHS backs free behavioural change app for type 2 diabeticsNHS England has awarded a contract to tech company Changing Health to develop a free app to help Share XNHS backs free behavioural change app for type 2 diabeticshttps://pharmaphorum.com/news/nhs-backs-free-behavioural-change-app-for-type-2-diabetics/
Celltrion buys drug portfolio from Takeda, ventures into chronic diseasesSouth Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Share XCelltrion buys drug portfolio from Takeda, ventures into chronic diseaseshttps://pharmaphorum.com/news/celltrion-ventures-into-chronic-diseases-with-takeda-portfolio-buy/
FDA approves new heart failure use for AZ’s FarxigaThe FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in Share XFDA approves new heart failure use for AZ’s Farxigahttps://pharmaphorum.com/news/fda-approves-new-heart-failure-use-for-azs-farxiga/
AZ maintains 2020 guidance as Q1 sales grow despite pandemicThe ongoing pandemic will not affect AstraZeneca’s performance in 2020, the company has said after its first quarter results Share XAZ maintains 2020 guidance as Q1 sales grow despite pandemichttps://pharmaphorum.com/news/az-maintains-2020-guidance-as-q1-sales-grow-despite-pandemic/
